search
Back to results

Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy

Primary Purpose

Uveal Melanoma

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
CITICOLINE
PLACEBO
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Uveal Melanoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • over 18 years old
  • uveal melanoma with posterior marge located at less than 3 mm of optic papilla
  • uveal melanoma treated with proton beam therapy with irradiation of optic head nerve
  • visual acuity before proton beam therapy over 30 letters (with ETDRS test)

Exclusion Criteria:

  • antecedent of acute glaucoma with angle enclosure
  • antecedent of chronical glaucoma with angle aperture
  • antecedent of optic neuropathy optique of congenital, ischemic, inflammatory or other origins
  • antecedent of neovascular glaucoma

Sites / Locations

  • CHU de NICE
  • Ophtalmology Departement, St Roch Hopital, Nice University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

CITICOLINE

Placebo

Arm Description

Daily oral administration of 800 mg citicoline

Daily oral administration of placebo

Outcomes

Primary Outcome Measures

Occurrence and delay of occurrence of radiation optic neuropathy
Occurrence and delay of occurrence of radiation optic neuropathy in patients treated for uveal melanomas with proton beam therapy

Secondary Outcome Measures

Visual function assessment
Best corrected visual acuity (ETDRS) ; Pattern ERG ; Visual Evoked potentials; adverse events

Full Information

First Posted
April 18, 2011
Last Updated
February 6, 2018
Sponsor
Centre Hospitalier Universitaire de Nice
Collaborators
DENSMORE pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01338389
Brief Title
Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Official Title
Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Unknown status
Study Start Date
June 25, 2012 (Actual)
Primary Completion Date
June 29, 2013 (Actual)
Study Completion Date
June 29, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice
Collaborators
DENSMORE pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Proton beam irradiation is the treatment of choice for uveal melanomas. It has favorable results in causing tumor regression while preserving the eye. Optic neuropathy has emerged consistently as an irreversible cause of visual loss in proton beam irradiated eyes. No neuroprotective strategies are available at present. Citicoline is a choline agent precursor available as a dietary supplement. Citicoline conferred acute neuroprotection and enhanced neuroplasticity in experimental stroke models. In ophthalmology, citicoline has demonstrated a significant action in improving retinal and cortical responses in patients with optic nerve diseases (glaucoma, ischemic optic neuropathy). Citicoline also exhibits a very low toxicity profile in humans. The purpose of the study is to demonstrate whether daily oral administration of citicoline in patients treated for uveal melanomas with proton beam therapy, prevents or delays the occurrence of radiation optic neuropathy. Changes in visual acuity, Pattern ERG and visual evoked potentials are measured. The tolerability/safety of the product is also evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uveal Melanoma

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CITICOLINE
Arm Type
Experimental
Arm Description
Daily oral administration of 800 mg citicoline
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Daily oral administration of placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
CITICOLINE
Intervention Description
Oral administration of CITICOLINE: Form: Powder for solution Dosage: 800mg per day duration: 5 years
Intervention Type
Dietary Supplement
Intervention Name(s)
PLACEBO
Intervention Description
Oral administration of placebo: Form: Powder for solution duration: 5 years
Primary Outcome Measure Information:
Title
Occurrence and delay of occurrence of radiation optic neuropathy
Description
Occurrence and delay of occurrence of radiation optic neuropathy in patients treated for uveal melanomas with proton beam therapy
Time Frame
Every 6 months
Secondary Outcome Measure Information:
Title
Visual function assessment
Description
Best corrected visual acuity (ETDRS) ; Pattern ERG ; Visual Evoked potentials; adverse events
Time Frame
Every 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: over 18 years old uveal melanoma with posterior marge located at less than 3 mm of optic papilla uveal melanoma treated with proton beam therapy with irradiation of optic head nerve visual acuity before proton beam therapy over 30 letters (with ETDRS test) Exclusion Criteria: antecedent of acute glaucoma with angle enclosure antecedent of chronical glaucoma with angle aperture antecedent of optic neuropathy optique of congenital, ischemic, inflammatory or other origins antecedent of neovascular glaucoma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stéphanie BAILLIF-GOSTOLI, MD
Organizational Affiliation
Ophtalmology department, Nice University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de NICE
City
Nice
ZIP/Postal Code
06000
Country
France
Facility Name
Ophtalmology Departement, St Roch Hopital, Nice University Hospital
City
Nice
ZIP/Postal Code
06000
Country
France

12. IPD Sharing Statement

Learn more about this trial

Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy

We'll reach out to this number within 24 hrs